News

Pinterest, Inc. (NYSE:PINS) is one of the stocks in Jim Cramer’s game plan for this week. Cramer highlighted that he expects ...
Banco BBVA Argentina S.A. (NYSE:BBAR) is one of the top NYSE stocks with the highest upside potential. On May 20, Itau BBA ...
Cerence Inc. exceeded Q3 2025 revenue guidance with $62.2M, raised full-year outlook, and highlighted AI-driven growth in automotive and non-auto markets.
Q3 2025 Management View Fusen Ernie Chen, President and CEO, highlighted ongoing efforts to "extend our market access through ...
Key Points Grand Canyon Education (NASDAQ:LOPE) exceeded analyst expectations with non-GAAP EPS of $1.53 and revenue of $247.5 million in Q2 2025. Enrollment growth remained strong, with total partner ...
News Corp has reported a 1% lift in fourth-quarter revenue, beating analyst estimates following strong performances in its real estate and Dow Jones divisions.
Orezone Gold Corporation (TSX: ORE, OTCQX: ORZCF) (“Orezone”) will announce its second quarter 2025 results on Wednesday, August 13, 2025, after market close. The announcement will be followed by an ...
At most, the next rate cut could be likely in Q3 2025-26, the Bank of Baroda Economist wrote in a report. However, since the inflation forecast for both Q4 2025-26 and Q1 2026-27 is above the 4 per ...
RESTON, Va. (AP) — RESTON, Va. (AP) — CACI International Inc. (CACI) on Wednesday reported fiscal fourth-quarter profit of $157.9 million. On a per-share basis, the Reston, Virginia-based company said ...
Gene Mack, CEO, Gain Therapeutics, explains how the company’s Magellan AI platform analyzes novel protein binding sites to identify and design drug candidates beyond what’s currently available in the ...
Announces positive data for rosnilimab, a pathogenic T cell depleter, through Week 38 from Phase 2b rheumatoid arthritis trialEnrollment completed for rosnilimab Phase 2 ulcerative colitis trial; ...
NDA for icotrokinra for the treatment of adults and adolescents 12 years of age and older with moderate to severe plaque psoriasis (PsO) submitted to U.S. FDA in July ...